4507:TYO
Shionogi & Co Ltd
Â¥2,827.00
arrow_downward
-0.14%(-4.00) 1D
Sep 11, 3:30:00 PM GMT+9 · JPY
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4507...
Open
Â¥2,818
High
Â¥2,834
Low
Â¥2,790
Mkt. cap
2.51T
Avg. vol.
2.66M
Volume
3.36M
Dividend
2.51%
Quarterly dividend
Â¥18
Ex-dividend date
Sep 29, 2026
P/E ratio
9.13
52-wk high
Â¥3,758
52-wk low
Â¥2,392
EPS
Â¥310
Shares outstanding
314.50M
No. of employees
6K
Open
Â¥2,818
High
Â¥2,834
Low
Â¥2,790
Mkt. cap
2.51T
Avg. vol.
2.66M
Volume
3.36M
Dividend
2.51%
Quarterly dividend
Â¥18
Ex-dividend date
Sep 29, 2026
P/E ratio
9.13
52-wk high
Â¥3,758
52-wk low
Â¥2,392
EPS
Â¥310
Shares outstanding
314.50M
No. of employees
6K
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees6.22K
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com